Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

0.7%
Female
99.3%
Male

Age Information

The average age of patients reporting adverse events with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN is 72.9 years.

Geographic Distribution

The majority of adverse event reports for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN originate from US.

Report Summary & Outcomes

10,716
Total Reports
10,716
As Primary/Secondary Suspect
1,461
Deaths Reported
545
Hospitalizations
61
Life-Threatening
34
Disabilities

Reporting Timeline

First adverse event report: 20130101. Most recent report: 20250915. View full timeline →

More About LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Full Profile Reports by Year Drug Interactions